The Risks of Developing Hypothyroidism With Immune Checkpoint Inhibitors

Abstract

Purpose/Objective(s): Characterize longitudinal change in swallowing related quality of life during and after intensity modulated proton therapy (IMPT) for oropharyngeal cancer. Materials/Methods: The MD Anderson Dysphagia Inventory (MDADI) was administered prospectively at baseline, end of IMPT, and 10 weeks, and 6 , 12, and 24 months after IMPT as part of a prospective proton therapy registry. MDADI 19-item composite and subscale scores were plotted longitudinally. Pairwise tests were Bonferroni corrected for multiple comparisons (P<.003). Results: Sixty-six patients with a mean age of 62 were included. Almost all had stage III/IV disease (96%) and 71% were treated with concurrent chemotherapy. A majority had T1-T2 primary tumors (80%); 84% had p16 positive disease and 41% were never smokers. Mean composite MDADI was 88.2AE13.4 at baseline, dropping significantly to a nadir of 59.4AE14.2 at end of IMPT (P<.001) with significant partial recovery by 10 weeks post-IMPT to 74.9AE14.2 (P<.001) with stable average performance thereafter through 2 years (P>.003 compared to previous time point). Poor MDADI (score<60) were reported in 7%, 61%, 20%, and 13% of patients at baseline, end-IMPT, 10 weeks, and 2 years after IMPT, with 14% of